🇺🇸 FDA
Patent

US 10548899

Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity

granted A61KA61K31/517A61K31/53

Quick answer

US patent 10548899 (Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity) held by Takeda Pharmaceutical Company Limited expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/517, A61K31/53, A61P, A61P25/04